Market analysis for IBS-positioned probiotic supplements in 20 countries

€500

About the report

Published July 2018. There are between 140 and 580 million IBS sufferers, many undiagnosed, and within this group more than 220 million young women in need of nutritional support for IBS symptoms. A growing body of research backs probiotic and synbiotic supplements to offer real benefits to hundreds of millions of Irritable Bowel Syndrome (IBS) sufferers globally. This report examines online retailing, regulatory, marketing as well as scientific data and trends in 20 countries to pry open a niche but expanding sector bristling with business opportunity.

What this report tells you

  • The IBS relief landscape: Background, what countries and how many people are affected.
  • The evolution of probiotics as a mean to relieve IBS symptoms and what  populations new products could target.
  • Rising awareness of IBS in the context of the “Amazon age” and how new IBS-positioned products can flourish.
  • Special focus on countries with exciting opportunities for this niche: China, Australia, North America, Europe and South Africa. Includes case studies on existing products in these markets.
  • The prevalence of IBS claims on-pack and which countries lead on this.
  • Overview of strains: Which are dominant, which countries have largest strain diversity for IBS-positioned products, what species are used to tackle IBS-symptoms, breakdown of major probiotic suppliers and an examination of other probiotic blends.
  • Conclusion and recommendations.
  • Appendix of studies relating to the relief of IBS symptoms.
  • Global picture
  • Country & strain focus:
    • China
    • Australia
    • North America
    • Europe
    • South Africa
  • IBS claims and science